Peer-reviewed veterinary case report
Maropitant reduces vomiting in female dogs given hydromorphone
By Claude, A K et al.·Published in Journal of veterinary internal medicine·2014·Mississippi State College of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs.
- Species:
- dog
Plain-English summary
A group of 60 mixed-breed female dogs scheduled for spaying were given hydromorphone, a pain medication, which often causes vomiting. To prevent this, some dogs received maropitant, an anti-nausea medication, before the hydromorphone, while others received acepromazine or a saline solution. The results showed that dogs given maropitant before hydromorphone had no vomiting, while those given saline had a high rate of vomiting. Although maropitant was effective in reducing vomiting, it did lead to increased drooling in some dogs. Overall, maropitant is a good option to prevent vomiting when using hydromorphone in dogs.
People also search for: dog vomiting after surgery · anti-nausea medication for dogs · maropitant for dog vomiting · hydromorphone side effects in dogs
Abstract
BACKGROUND: Vomiting is a common complication associated with the use of hydromorphine for pre-emptive analgesia in dogs. The ideal anti-emetic protocol for prevention of this complication has not been established. HYPOTHESIS: Maropitant administered concurrently or before hydromorphone would reduce the incidence of vomiting, signs of nausea, ptyalism, and increased panting compared to administration of acepromazine or a 0.9% saline control. ANIMALS: Sixty mixed-breed female dogs scheduled for ovariohysterectomy. METHODS: Randomized, blinded, placebo-controlled experimental study. Dogs were assigned to 4 experimental groups with 15 dogs per group. All groups received 0.2 mg/kg of hydromorphone IM. Group "Control" received 0.1 mL/kg saline SC 30-45 minutes before hydromorphone, group "Marop1" received 1 mg/kg maropitant SC 30-45 minutes before hydromorphone, group "Ace" received 0.02 mg/kg IM acepromazine 30-45 minutes before hydromorphone, and group "Marop2" received 1 mg/kg SC maropitant concurrently with hydromorphone. A trained and blinded observer documented adverse events from the time hydromorphone was administered until the time dogs were induced for surgery. RESULTS: Marop1 had significantly less vomiting (0%) compared to Control (87%; P < .01) and Ace (53%; P < .01). Marop2 had significantly less vomiting (27%) compared to Control (P < .01). Marop1 had significantly greater incidence of ptyalism (73%) compared to Ace (P < .01; 20%). Ace showed significantly less panting (33%) compared to Marop2 (93%; P < .01). CONCLUSIONS AND CLINICAL IMPORTANCE: In healthy dogs, maropitant citrate administered before hydromorphone significantly decreases the incidence of vomiting in dogs but does not improve signs of nausea, ptyalism, or increased panting.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25146756/